AstraZeneca`s Luxomiti (Moxetumomab pasudotox tdfk) Receives Supplemental Approval in US
Astrazeneca AB`s Lumoxiti (Moxetumomab Pasudotox - TDFK) Receives Supplemental Approval in US
(RTTNews) - Innate Pharma SA (IPHA) said that the European Medicines Agency accepted the Marketing Authorization Application or MAA for Lumoxiti, a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia or HCL who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
AstraZeneca’s Calquence has been battling it out in mantle cell lymphoma since it won its first approval back in late 2017, but all along, the company has had its eye on another disease: chronic lymphocytic leukemia. And that’s where it’s scored its latest win.
France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official title will be EVP and general manager of Innate Pharma US. Most recently, she was chief business officer, chief commercial officer and head of US operations at Tessa Therapeutics.
French company Innate Pharma have announced the appointment of Jennifer Butler to the position of Executive Vice President and General Manager.
Astrazeneca's Lumoxiti (Moxetumomab Pasudotox-Tdfk) Receives Approval in US
AZ, however, isn’t the only Big Pharma company to have closed manufacturing operations in Colorado in recent years. Back in 2017, Novartis said it would close a Sandoz plant in Broomfield, Colorado, over two years. Pricing pressure in its U.S. portfolio was cited as a reason for the discontinuation. Almost at the same time, Pfizer agreed to sell a legacy Hospira API facility in Boulder to CDMO CordenPharma.
AstraZeneca digs deeper into cancer with Innate stake